醫藥股隨A股同業受捧 諾誠健華、科濟及信達急漲11%-15%
恆指午後曾抽升至16,883(再度逼近今早所造高位16,896),現報16,841,升228點或1.43%,總成交額661億元。
A股醫藥生物、中藥概念、流感及新冠藥物板塊急漲2.6%-3.9%居升幅榜首。本港醫藥股近日普遍跑贏大市,尤其是信達生物(01801.HK)四連升,尤其是今天股價升破50天線(29.2元),最高見29.9元,現報29.66元,急漲15%,成交維持活躍仍達1,716萬股。科濟藥業-B(02171.HK)繼昨天整固後,今天股價升破20天線(11.4元)高見12.56元,現報12.4元,急漲14.6%,成交增至352萬股。
諾誠健華-B(09969.HK)五連升,最高見9.79元,現報9.65元,急漲11%;諾誠健華(688428.SH)急漲17%報11.97元人民幣。
金斯瑞生物(01548.HK)升破20天線(16.98元),最高見17.66元,現報17.4元,漲逾8%。中國中藥(00570.HK)繼昨天整固後,今天股價升破50天線(3.1元),最高見3.27元,現報3.24元,回升8%。康方生物(09926.HK)三連升,最高見29.4元,為今年1月以來最高,現報28.9元,續升6%。威高股份(01066.HK)五連升,今天股價12.18元,創近一年高,現報12.06元,續升逾5%。
復星醫藥(02196.HK)、歌禮製藥(01672.HK)、康龍化成(03759.HK)、康希諾(06185.HK)、藍籌中生製藥(01177.HK)和石藥(01093.HK)、君實生物(01877.HK)及開拓藥物(09939.HK)升逾2.5%-4%。
此外,三大線上醫療平台京東健康(06618.HK)、平安好醫生(01833.HK)及藍籌阿里健康(00241.HK)依次升3.3%-6.9%,後者追落後曾高見3.56元。
然而,藍籌藥明生物(02269.HK)連續第二天反覆回吐,高低見51.65元/48.3元,現報49.5元,反覆續跌1.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.